Hedy Smith, MD
Hematology · Boston, MANPI 1255399895
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Global Blood Therapeutics, Inc. at 35.3% of the total. Reporting peaked in 2021 at $9,300 and has fallen 72.4% since, to $2,567 in 2025.
Across 92 payments — averaging $229.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$7K
- Pfizer$7K
- Agios Pharmaceuticals, Inc.$2K
- Alnylam Pharmaceuticals Inc.$2K
- Incyte Corporation$493
- Chiesi USA, Inc.$325
- plus $2K from 24 others
Across 53 payments — averaging $5001.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$134K
- Novartis$73K
- AbbVie$59K
What the payments were for
- Consulting fees$9,07043%
- Speaking & faculty fees$6,27530%
- Travel & lodging$2,51412%
- Food & beverage$2,91614%
- Education$3342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 3 | $7,445 |
| Pfizer | 9 | $7,378 |
| Agios Pharmaceuticals, Inc. | 10 | $2,068 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,755 |
| Incyte Corporation | 9 | $493 |
| Chiesi USA, Inc. | 2 | $325 |
| Bristol Myers Squibb | 9 | $264 |
| Novartis | 4 | $195 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $124 |
| Merck | 5 | $112 |
| Servier Pharmaceuticals LLC | 5 | $101 |
| GSK | 4 | $94 |
| AstraZeneca | 4 | $89 |
| Janssen Scientific Affairs, LLC | 1 | $74 |
| Astellas Pharma US Inc | 1 | $70 |
| Johnson & Johnson | 3 | $63 |
| AbbVie | 2 | $59 |
| Sanofi | 2 | $56 |
| Amgen | 2 | $50 |
| Sobi, Inc | 2 | $46 |
| AVEO Pharmaceuticals, Inc. | 1 | $45 |
| Caris MPI, Inc. | 1 | $35 |
| Mirati Therapeutics, Inc. | 1 | $30 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Gilead | 1 | $23 |
| Morphosys, US Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,109 in reported general payments places this provider in the 70th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 33 | $490,395 |
| NinlaroIxazomib Citrate | 22 | $277,280 |
| SprycelDasatinib | 11 | $187,863 |
| CalquenceAcalabrutinib Maleate | 11 | $167,960 |
| ProcritEpoetin Alfa | 11 | $122,130 |
| VenclextaVenetoclax | 21 | $68,209 |
| EliquisApixaban | 17 | $10,462 |
| Hydroxyurea | 49 | $1,392 |
| Oxycodone Hcl | 42 | $489 |
| Acyclovir | 52 | $383 |
| Methadone Hcl | 13 | $184 |
| Hydromorphone Hcl | 12 | $131 |
| Clonazepam | 11 | $71 |
| Ondansetron Hcl | 12 | $63 |
| Ibuprofen | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $264 | $490,39533 claims |
| AstraZenecaCalquence | $89 | $167,96011 claims |
| Johnson & JohnsonProcrit | $63 | $122,13011 claims |
| AbbVieVenclexta | $59 | $68,20921 claims |
| PfizerEliquis | $7,378 | $10,46217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 77 hematology providers in Massachusetts.
Other hematology in Boston
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.